MX2019012461A - Anticuerpo anti-pd-l1 y uso del mismo. - Google Patents

Anticuerpo anti-pd-l1 y uso del mismo.

Info

Publication number
MX2019012461A
MX2019012461A MX2019012461A MX2019012461A MX2019012461A MX 2019012461 A MX2019012461 A MX 2019012461A MX 2019012461 A MX2019012461 A MX 2019012461A MX 2019012461 A MX2019012461 A MX 2019012461A MX 2019012461 A MX2019012461 A MX 2019012461A
Authority
MX
Mexico
Prior art keywords
antibodies
fully human
disclosed
affinity
human anti
Prior art date
Application number
MX2019012461A
Other languages
English (en)
Inventor
Lavrovsky Yan
Xu Ting
Repik Alexey
Samsonov Mikhail
Ignatiev Vasily
Barbashov Sergei
Archuadze Shorena
Original Assignee
R Pharm Overseas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Pharm Overseas Inc filed Critical R Pharm Overseas Inc
Publication of MX2019012461A publication Critical patent/MX2019012461A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se dan a conocer anticuerpos anti-PD-L1 completamente humanos y sus aplicaciones correspondientes. Los anticuerpos completamente humanos tienen la capacidad de enlazarse específicamente a PD-L1 de humano. Los anticuerpos se obtuvieron al emplear una técnica de prospección basada en una genoteca de despliegue en levadura y también por medio de la maduración de la afinidad para mejorar adicionalmente su afinidad por PD-L1. Los anticuerpos anti-PD-L1 completamente humanos dados a conocer muestran buena especificidad, afinidad y estabilidad. Éstos tienen la capacidad de mejorar la actividad de células T al enlazarse a células T activadas, mientras que inhiben significativamente el crecimiento de tumores. Los anticuerpos anti-PD-L1 completamente humanos dados a conocer se pueden usar en el diagnóstico y el tratamiento de cánceres relacionados con PD-L1 y otras enfermedades asociadas.
MX2019012461A 2017-04-18 2018-04-18 Anticuerpo anti-pd-l1 y uso del mismo. MX2019012461A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2017028206 2017-04-18
PCT/US2018/028206 WO2018195226A1 (en) 2017-04-18 2018-04-18 Anti-pd-l1 antibody and use thereof

Publications (1)

Publication Number Publication Date
MX2019012461A true MX2019012461A (es) 2019-12-11

Family

ID=63856823

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012461A MX2019012461A (es) 2017-04-18 2018-04-18 Anticuerpo anti-pd-l1 y uso del mismo.

Country Status (16)

Country Link
US (1) US20210115143A1 (es)
EP (1) EP3612565A4 (es)
JP (2) JP2020517239A (es)
KR (1) KR102323960B1 (es)
CN (1) CN110856446A (es)
AU (1) AU2018256392B2 (es)
BR (1) BR112019021828B1 (es)
CA (1) CA3059447A1 (es)
CL (1) CL2019002953A1 (es)
CO (1) CO2019012118A2 (es)
EA (1) EA201900443A1 (es)
MA (1) MA50038A (es)
MX (1) MX2019012461A (es)
PH (1) PH12019502302A1 (es)
SG (1) SG11201909041SA (es)
WO (1) WO2018195226A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3880698A4 (en) * 2018-11-14 2022-11-30 RubrYc Therapeutics, Inc. MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
JP7302010B2 (ja) * 2019-04-11 2023-07-03 スクリップス コリア アンチボディ インスティチュート プログラム細胞死タンパク質リガンド－１（ｐｄ－ｌ１）に対する抗体及びその用途
AU2020261961B2 (en) * 2019-04-26 2022-07-07 I-Mab Biopharma Co., Ltd. Human PD-L1 antibodies
WO2022006091A1 (en) * 2020-06-29 2022-01-06 Anovent Pharmaceutical (U.S.), Llc Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030113316A1 (en) * 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
CN102245640B (zh) * 2008-12-09 2014-12-31 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
EP3060581A4 (en) * 2013-10-25 2017-06-07 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
CA3156357A1 (en) * 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
CA2940242A1 (en) * 2014-02-20 2015-08-27 Alder Biopharmaceuticals, Inc. Anti-acth antibodies and use thereof
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CN114702586A (zh) * 2015-03-13 2022-07-05 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
EP3532100A4 (en) * 2016-10-30 2020-11-25 Shanghai Henlius Biotech, Inc. ANTI-PD-L1 ANTIBODIES AND VARIANTS

Also Published As

Publication number Publication date
KR102323960B1 (ko) 2021-11-10
AU2018256392B2 (en) 2024-05-16
AU2018256392A1 (en) 2019-10-17
WO2018195226A1 (en) 2018-10-25
EA201900443A1 (ru) 2020-03-06
EP3612565A4 (en) 2021-06-16
CL2019002953A1 (es) 2020-01-10
CN110856446A (zh) 2020-02-28
CO2019012118A2 (es) 2020-04-01
PH12019502302A1 (en) 2020-09-21
BR112019021828A2 (pt) 2020-03-24
US20210115143A1 (en) 2021-04-22
BR112019021828B1 (pt) 2022-09-20
MA50038A (fr) 2020-07-08
CA3059447A1 (en) 2018-10-25
EP3612565A1 (en) 2020-02-26
KR20190141169A (ko) 2019-12-23
JP2023025003A (ja) 2023-02-21
JP2020517239A (ja) 2020-06-18
SG11201909041SA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
PH12019502302A1 (en) Anti-pd-l1 antibody and use thereof
SA523442262B1 (ar) أجسام مضادة للارتباط بـ cd3
JOP20200237A1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
MX2021006786A (es) Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos.
MX2018016404A (es) Anticuerpos de union a cd3.
MX2020006715A (es) Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
MX2020002076A (es) Anticuerpos de b7-h4 y metodos para usarlos.
PH12017500994A1 (en) Anti-pd-1 antibodies and methods of use thereof
MX360543B (es) Anticuerpos st-2 humanos solubles y ensayos.
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
EA201491700A1 (ru) Человеческие антитела к cd27, методы и применение
WO2018226578A8 (en) Nectin-4 binding proteins and methods of use thereof
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
MX2024005669A (es) Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano.
MY187325A (en) Anti-5t4 antibodies and antibody-drug conjugates
NZ631543A (en) Antibodies to bradykinin b1 receptor ligands
MX2021009722A (es) Anticuerpos anti-trem2 y metodos para utilizarlos.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2021009727A (es) Anticuerpos que se unen al tejido tumoral para diagnóstico y tratamiento.
NZ602515A (en) Proteins that bind pi16 and uses thereof
WO2017160699A3 (en) Method of preventing graft versus host disease
MY187583A (en) Igf-1r antibody and its use for the diagnosis of cancer
MX2022003762A (es) Molécula de unión específica para el factor inhibidor de la leucemia (lif) y uso de la misma.